ClinicalTrials.gg
WithdrawnNCT05126342Updated Apr 6, 2025

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

A Phase 2 interventional study of Niraparib and Dostarlimab in Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer and Primary Peritoneal Cancer, sponsored by AGO Research GmbH. Withdrawn. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-06.

Sponsored by AGO Research GmbH · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Study has been withdrawn; was never submitted to Competent authority nor to ethics commitee.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing niraparib in Ovarian Neoplasms — 9 open to participants now, 14 under way, 2 of them phase 3. niraparib · Ovarian Neoplasms.

Enrollment
41st of 44
0 · median 41
Started
2023
with 3 others
Phase 2
18 of 44
5 open now
Registered
34th of 44
by date
Lead sponsor
1 of 44
AGO Research GmbH

Among the 44 studies testing niraparib in Ovarian Neoplasms, this one is the 41st largest by enrollment, is one of 4 that started in 2023, is one of 18 in phase 2, and was the 34th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

9 of the 44 studies testing niraparib in Ovarian Neoplasms are open now, in 10 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About niraparib

niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing niraparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

This is a multicenter, open-label, non-randomized pilot study (Phase II). The aim is to obtain evidence of efficacy of niraparib and dostarlimab (TSR-042) in patients with relapsed ovarian cancer in two experimental cohorts and to generate data on PARPi (Poly(ADP-ribose)-Polymerase inhibitor) resistance and predictive biomarkers for IO (Immuno-Oncology) and PARPi.

Read the detailed description

In total, 100 patients are planned to be enrolled in 2 cohorts (60 patients cohort A and 40 patients cohort B).

Cohort A: Recurrent ovarian-, fallopian tube, or primary peritoneal cancer with relapse after more than 6 months of PARPi maintenance therapy.

Cohort B: Recurrent ovarian-, fallopian tube, or primary peritoneal cancer with relapse within 6 months of PARPi maintenance therapy.

All patients must have a known status for BRCA1 and BRCA2 and one or two prior lines of chemotherapy. The last line of chemotherapy should have included platinum.

Both cohorts will receive the selective PARP 1/2 inhibitor niraparib in combination with the anti-PD-1 checkpoint inhibitor dostarlimab (TSR-042) for a maximum treatment duration of 2 years.

The overall objective of this study is to reveal insights in mechanisms of PARPi resistance in epithelial ovarian cancer (EOC) and to obtain preliminary evidence of the efficacy of sequential and/or simultaneous combined immuno-PARPi therapy.

03

Conditions studied

  • Recurrent Ovarian Cancer
  • Recurrent Fallopian Tube Cancer
  • Primary Peritoneal Cancer

Keywords

  • Recurrent Ovarian Cancer
  • Niraparib
  • Dostarlimab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Cohort A

  1. Patients with secondary PARPi resistance, i.e. those whose disease has first more than 6 months after PARPi maintenance therapy

    a. Criterion for relapse can be according to 1.1, CA-125 (GCIG) or clinical symptoms

    Cohort B

  2. Patients with primary PARPi resistance, i.e. those whose disease has relapsed within 6 months of PARPi maintenance therapy.

    a. Criterion for relapse can be according to RECIST 1.1, CA-125 (GCIG) or clinical symptoms

    Both cohorts

  3. Patients with relapsed serous, endometrioid or clear cell epithelial ovarian cancer.
  4. confirmed diagnosis (cytology alone excluded) of high-grade serous, endometrioid or clear cell ovarian carcinoma.
  5. Patients with one or two . The last line of chemotherapy should have included platinum.
  6. (ECOG) performance status 0-1.
  7. Estimated of at least 3 months.
  8. according to RECIST or evaluable disease (GCIG CA-125 criteria and other).
  9. Urgent chemotherapy not clinically needed according to physicians estimation.
  10. Formalin fixed, paraffin-embedded archival tumor available from the primary or recurrent cancer required for all patients.
  11. Tumor of the relapse is mandatory.
  12. Female patients must be >18 years of age.
  13. Signed and ability to comply with treatment and follow-up.
  14. Adequate organ function:

    1. (ANC) ≥1,5 x 10\^9/L
    2. ≥100 x 10\^9/L
    3. ≥9 g/dL
    4. Calculated ≥60 mL/min using Cockcroft-Gault equation
    5. Total ≤1.5 x OR direct bilirubin ≤1 x ULN, patients with documented Gilbert's syndrome total bilirubin ≤2.0 x ULN
    6. (AST) and alanine aminotransferase (ALT) ≤2.5 x ULN unless liver are present, in which case they must be ≤5 x ULN
  15. Adequately controlled blood pressure (BP), with a systolic BP of ≤140 mmHg and diastolic BP of ≤90 mmHg for eligibility. Patients must have a BP of ≤140/90 mmHg taken in the clinic setting by a medical professional within 2 weeks prior to day 1, cycle 1.
  16. For women of (WOCBP): agreement to remain abstinent (refrain from heterosexual intercourse) or use a highly effective method with a failure rate of \<1% per year during the study participation and for at least 6 months after administration of the last dose of medication. A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a state (≥12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries, fallopian tubes, and/or uterus).

    Examples of contraceptive methods with a failure rate of \<1% per year include but are not limited to bilateral tubal ligation and/or occlusion, male sterilization, and intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

  17. Negative urine or serum pregnancy test confirmed prior to treatment on day 1.

Exclusion criteria

Exclusion Criteria:

  1. Highly symptomatic disease according to physician´s discretion, i.e. rapid remission is required.
  2. Patients with mucinous endothelial ovarian cancer.
  3. Non-epithelial tumor origin of the ovary, the fallopian tube or the peritoneum (e.g. germ cell tumors).
  4. Ovarian tumors of low malignant potential (e.g. borderline tumors).
  5. other than ovarian cancer (EOC) within 5 years prior to registration, with the exception of those with a negligible risk of or death (e.g. 5-year OS rate >90%) and treated with expected curative outcome (such as adequately treated non melanoma skin carcinoma, ductal carcinoma in situ, or stage I low grade uterine cancer).
  6. More than two prior systemic anticancer regimens; maintenance therapies (e.g. with bevacizumab or PARPi) are not calculated as separate line.
  7. More than two lines of PARPi therapies.
  8. Administration of other simultaneous chemotherapy drugs, any other anticancer therapy or anti-neoplastic hormonal therapy, or simultaneous radiotherapy during the trial treatment period (hormonal replacement therapy is permitted).

    The following washout requirements for prior therapies/procedures must be observed:

    g. surgery: ≥3 weeks prior to therapy

    h. therapy: within 4 weeks or within less than at least 5 half-lives, whichever is shorter, prior to therapy

    i. radiation: radiation encompassing >20% of bone marrow ≤2 weeks prior to therapy

  9. Patient has any known history or current diagnosis of MDS or AML.
  10. Prior treatment with immune checkpoint blockade therapies, anti-PD1, or therapeutic antibodies or anti-CTLA4 or anti-TIM-3, or participating in AGO-OVAR 2.29 trial.
  11. Treatment with systemic immunostimulatory agents (including but not limited to interferon-alpha (IFN-α) and interleukin-2 (IL-2) within 4 weeks or five half-lives of the drug (whichever is longer) prior to cycle 1, day 1.
  12. Treatment with systemic or other systemic medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents) within 2 weeks prior to cycle 1, day 1, or anticipated requirement for systemic immunosuppressive medications during the trial.

    NOTE: The use of inhaled corticosteroids for , mineralocorticoids (e.g. fludrocortisone) for patients with orthostatic hypotension, and low-dose supplemental corticosteroids for adrenocortical insufficiency are allowed.

  13. Administration of a live, attenuated vaccine within 30 days prior to cycle 1, day 1 or anticipation that such a will be required during the study or within 5 months after the last dose of the investigational drugs. Influenza vaccination should be given during influenza season only. Patients must not receive live, attenuated influenza vaccination, for more information see section 5.9.2.
  14. Current treatment with anti-viral therapy for .
  15. History of idiopathic pulmonary fibrosis (including pneumonitis), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) detected on screening chest CT scan is permitted.
  16. Patients with a baseline >470 milliseconds.
  17. Patients that are receiving concomitant medications that prolong QTc and are unable to discontinue use for the duration of the study.
  18. History or clinical suspicion of or spinal cord compression. CT/MRI of the brain is mandatory (within 4 weeks prior to registration) in case of suspected brain metastases. Spinal MRI is mandatory (within 4 weeks prior to registration) in case of suspected spinal cord compression.
  19. History of disease, including but not limited to dermatomyositis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with anti-phospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
  20. Immunocompromised patients, e.g. patients who are known to be serologically positive for (HIV). Patients with active hepatitis B (defined as having a positive hepatitis B surface antigen [HBsAg] test at screening) or Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as having a negative HBsAg test and a positive antibody to hepatitis B core antigen [anti-HBc] antibody test) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.
  21. Persistent toxicities (≥ grade 2) with the exception of alopecia and neurotoxicity CTCAE grade 2.
  22. Severe infection requiring oral or IV antibiotics within 4 days prior to registration, including but not limited to active tuberculosis or hospitalization for complications of infection, bacteraemia, or severe pneumonia. Patients receiving prophylactic antibiotics (e.g., to prevent urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.
  23. Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment related complications.
  24. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection and posterior reversible encephalopathy syndrome (PRES). This includes also any psychiatric disorder that prohibits obtaining .
  25. Pregnancy, lactation, or intention to become pregnant and Women of (WOBCP) not protected by highly-effective methods, including male contraception (e.g. condoms as a barrier method), during the study or within 6 months after the last dose of niraparib or dostarlimab.
  26. Known to infused protein products and to the components of niraparib or dostarlimab.
  27. Participant has received colony stimulating factors (e.g., granulocyte colony-stimulating factor, granulocyte macrophage colony stimulating factor, or recombinant erythropoietin) within 4 weeks prior to initiating protocol therapy.
  28. Participant has had any known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted >4 weeks and was related to the most recent treatment.
  29. Participant has received a transfusion ( or red blood cells) ≤4 weeks prior to initiating protocol therapy.
Terms in these criteria, in plain language(35)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Cohort A

    Recurrent ovarian-, fallopian tube, or primary peritoneal cancer with relapse after more than 6 months of PARPi maintenance therapy.

    Drug: Niraparib · Drug: Dostarlimab

  • Experimental
    Cohort B

    Recurrent ovarian-, fallopian tube, or primary peritoneal cancer with relapse within 6 months of PARPi maintenance therapy.

    Drug: Niraparib · Drug: Dostarlimab

Interventions

  • Niraparib starting dose of study treatment will be based upon the patient's baseline body weight and baseline platelet count. Patients with a baseline body weight ≥77 kg and baseline platelet count ≥150 x 10\^9/L may start with niraparib 300 mg (3 x 100 mg capsules) daily unless the dose has not already been reduced to 200 mg in a prior treatment line. Patients with a baseline body weight \<77 kg or a baseline platelet count \<150 x 10\^9/L will be administered niraparib 200 mg (2 x 100 mg capsules) daily.

    Also known as: Zejula

  • Dostarlimab (TSR-042) is administered 500 mg iv Q3W for the first 12 weeks. For the remainder of the study dostarlimab (TSR-042) is administered 1000 mg iv Q6W.

    Also known as: TSR-042

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Defined as Complete Response rate (CR) plus Partial Response Rate (PR) according to RECIST 1.1 assessments

    Time frame: At week 16 of treatment

Secondary outcomes

  1. Response Rate

    Defined as number of patients with Complete Response rate (CR) and Partial Response Rate (PR) according to iRECIST assessments.

    Time frame: At week 16 of treatment

  2. Median Progression Free Survival (PFS)

    Defined as the time from randomization to first Progressive Disease (PD) or death, whichever occurs earlier. PD is based on investigators assessment using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1 and iRECIST).

    Time frame: At 6 months

  3. 6 months Progression Free Survival (PFS) rate

    Defined as the time from randomization to first progressive disease (PD) or death, whichever occurs earlier. PD is based on investigators assessment using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1 and iRECIST).

    Time frame: At 6 months

  4. Disease Control Rate (DCR)

    Defined as sum of Stable Disease (SD), Partial Response (PR) and Complete Response (CR)

    Time frame: At 16 weeks

  5. Overall Survival (OS)

    Defined as time from start of treatment to death

    Time frame: At 12 months

  6. Time from registration to start of first subsequent therapy (TFST)

    Time from registration to start of first subsequent therapy or death, whichever occurs earlier

    Time frame: Up to approximately 40 months

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2023; primary completion for Nov 2024, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2021
First posted
Nov 19, 2021
StartEst.
Nov 1, 2023
Primary completionEst.
Nov 1, 2024
CompletionEst.
Nov 1, 2026
Last update
Apr 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05126342
Lead sponsor
AGO Research GmbH
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 19, 2021
Start date
Nov 1, 2023 (estimated)
Primary completion
Nov 1, 2024 (estimated)
Completion
Nov 1, 2026 (estimated)
Last update
Apr 6, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Niraparib · Dostarlimab

Start the discussion